{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:11:24Z","timestamp":1783163484306,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41440-023-01260-8","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:03:34Z","timestamp":1680001414000},"page":"1525-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A systematic review and meta-analysis of the clinical impact of stopping renin\u2013angiotensin system inhibitor in patients with chronic kidney disease"],"prefix":"10.1038","volume":"46","author":[{"given":"Takashin","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Mitsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"1260_CR2","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048\u201350.","journal-title":"Kidney Int"},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975\u201382.","journal-title":"Lancet."},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372.","journal-title":"Circulation."},{"key":"1260_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455\u201369.","journal-title":"Eur Heart J"},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.ki.5002273","volume":"72","author":"PE Stevens","year":"2007","unstructured":"Stevens PE, O\u2019Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92\u20139.","journal-title":"Kidney Int"},{"key":"1260_CR8","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1681\/ASN.2014101034","volume":"26","author":"SD Navaneethan","year":"2015","unstructured":"Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol. 2015;26:2512\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","volume":"42","author":"E Mishima","year":"2019","unstructured":"Mishima E, Haruna Y, Arima H. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. Hypertens Res. 2019;42:469\u201382.","journal-title":"Hypertens Res"},{"key":"1260_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"1260_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80:797\u2013811.","journal-title":"Drugs."},{"key":"1260_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension."},{"key":"1260_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1260_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group.","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2021;99:S1\u201387.","journal-title":"Kidney Int Suppl"},{"key":"1260_CR15","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156\u201362.","journal-title":"Arch Intern Med"},{"key":"1260_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"MR Weir","year":"2010","unstructured":"Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531\u201348.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.2215\/CJN.03830318","volume":"13","author":"SD Navaneethan","year":"2018","unstructured":"Navaneethan SD, Akeroyd JM, Ramsey D, Ahmed ST, Mishra SR, Petersen LA, et al. Facility-level variations in kidney disease care among veterans with diabetes and CKD. Clin J Am Soc Nephrol. 2018;13:1842\u201350.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1260_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","volume":"94","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Shin JI, Sang Y, Inker LA, Secora A, Luo S, et al. Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Mayo Clin Proc. 2019;94:2220\u20139.","journal-title":"Mayo Clin Proc"},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","volume":"25","author":"AK Ahmed","year":"2010","unstructured":"Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transpl. 2010;25:3977\u201382.","journal-title":"Nephrol Dial Transpl"},{"key":"1260_CR20","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2:e1918169.","journal-title":"JAMA Netw Open"},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, et al. Real-world associations of renin\u2013angiotensin\u2013aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8:e012655.","journal-title":"J Am Heart Assoc"},{"key":"1260_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1470320313507122","volume":"15","author":"JH Lee","year":"2014","unstructured":"Lee JH, Kwon YE, Park JT, Lee MJ, Oh HJ, Han SH, et al. The effect of renin\u2013angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia. J Renin Angiotensin Aldosterone Syst. 2014;15:491\u20137.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020;180:718\u201326.","journal-title":"JAMA Intern Med"},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"EL Fu","year":"2021","unstructured":"Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol. 2021;32:424\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"1260_CR25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/ndt\/gfaa300","volume":"36","author":"CP Walther","year":"2021","unstructured":"Walther CP, Winkelmayer WC, Richardson PA, Virani SS, Navaneethan SD. Renin\u2013angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transpl. 2021;36:1893\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80:164\u201373.","journal-title":"Am J Kidney Dis"},{"key":"1260_CR27","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.eclinm.2022.101751","volume":"55","author":"A Yang","year":"2022","unstructured":"Yang A, Shi M, Lau ESH, Wu H, Zhang X, Fan B, et al. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study. EClinicalMedicine. 2022;55:101751.","journal-title":"EClinicalMedicine"},{"key":"1260_CR28","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021\u201332.","journal-title":"N Engl J Med"},{"key":"1260_CR29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"key":"1260_CR30","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA."},{"key":"1260_CR31","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"key":"1260_CR32","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ."},{"key":"1260_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1260_CR34","unstructured":"GRADEpro GDT. GRADEpro guideline development tool [Software]. McMaster University; 2020 (developed by Evidence Prime, Inc.). https:\/\/www.gradepro.org\/."},{"key":"1260_CR35","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ."},{"key":"1260_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","volume":"111","author":"HJ Sch\u00fcnemann","year":"2019","unstructured":"Sch\u00fcnemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105\u201314.","journal-title":"J Clin Epidemiol"},{"key":"1260_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ndt\/gfx064","volume":"33","author":"S Chinnappa","year":"2018","unstructured":"Chinnappa S, White E, Lewis N, Baldo O, Tu YK, Glorieux G, et al. Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2018;33:450\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1260_CR38","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/ndt\/12.4.718","volume":"12","author":"N Joki","year":"1997","unstructured":"Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant. 1997;12:718\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"1260_CR39","first-page":"99","volume":"3","author":"S Said","year":"2014","unstructured":"Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3:99\u2013104.","journal-title":"J Nephropathol"},{"key":"1260_CR40","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group.","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet."},{"key":"1260_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","volume":"93","author":"PI Georgianos","year":"2018","unstructured":"Georgianos PI, Agarwal R. Revisiting RAAS-blockade in CKD with newer potassium binding drugs. Kidney Int. 2018;93:325\u201334.","journal-title":"Kidney Int"},{"key":"1260_CR42","doi-asserted-by":"crossref","unstructured":"Tonelli M, Wiebe N, James MT, Klarenbach SW, Manns BJ, Ravani P, et al. A population-based cohort study defines prognoses in severe chronic kidney disease. Kidney Int. 2018;93:1217\u20131226.","DOI":"10.1016\/j.kint.2017.12.013"},{"key":"1260_CR43","doi-asserted-by":"crossref","unstructured":"Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, et al. Hyperkalemia and renin\u2013angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS ONE. 2019;14:e0213192.","DOI":"10.1371\/journal.pone.0213192"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01260-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01260-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01260-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T23:06:20Z","timestamp":1685919980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01260-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01260-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}